# US 2012/0258081 A1 · Methods of treating proliferative diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0258081 A1
- Document ID: US20120258081A1
- Status: Published application
- Kind: A1
- Application number: 13/320,217
- Filed: 2010-05-14
- Published: 2012-10-11
- Earliest claimed: 2009-05-14
- Assignees: Ambit Biosciences Corporation
- Inventors: Robert E. Corringham; Patrick B. O'Donnell; Joyce K. James
- Web page: https://patentgrep.com/patent/US20120258081A1

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/145: {with organic compounds}
- A61K 9/1641: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/429: condensed with heterocyclic ring systems
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients, including a specific patient population. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.

## Claims

### Claim 1

A method of treating a proliferative disease in a patient, which comprises administering to the mammal having or suspected to have the proliferative disease, a therapeutically effective amount of the compound of Formula I:
or a pharmaceutically acceptable salt or solvate thereof, wherein the therapeutically effective amount is at least about 12 mg per day, and wherein the compound is administered on an empty stomach.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound is administered at least about 2 hours after meal.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound is administered about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 hours after meal.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound is administered about 1, 2, 3 or 4 hours before meal.

### Claim 5 (depends on 1)

The method of claim 1, wherein the compound is administered at least about 2 hours after and about 1 hour before meal.

### Claim 6 (depends on 1)

The method of claim 1, where in the disease is acute myeloid leukemia.

### Claim 7 (depends on 1)

The method of claim 1, where in the disease is relapsed or refractory acute myeloid leukemia.

### Claim 8 (depends on 1)

The method of claim 1, wherein the patient is relapsed after a first line cancer therapy or a second line cancer therapy or is refractory to a cancer therapy.

### Claim 9 (depends on 1)

The method of claim 1, wherein the patient is 60 years or older and relapsed after a first line cancer therapy.

### Claim 10 (depends on 1)

The method of claim 1, wherein the patient is 18 years or older and is relapsed after a second line cancer therapy.

### Claim 11 (depends on 1)

The method of claim 1, wherein the patient is 60 years or older and is refractory to a first line cancer therapy or 18 years or older and is refractory to a second line therapy.

### Claim 12 (depends on 1)

The method of claim 1, wherein the patient is 70 years or older and is previously untreated or is ineligible and/or unlikely to benefit from cancer therapy.

### Claim 13 (depends on 1)

The method of claim 1, wherein the patient is 75 years or older.

### Claim 14 (depends on 13)

The method of claim 13, wherein the patient has prior myelodysplastic syndrome, unfavorable cytogenetics at diagnosis, or ECOG performance status of 2.

### Claim 15 (depends on 1)

The method of claim 1, wherein the amount is about 300 mg per day.

### Claim 16 (depends on 1)

The method of claim 1, wherein the amount is about 200 mg per day.

### Claim 17 (depends on 1)

The method of claim 1, wherein the amount is about 150 mg per day.

### Claim 18 (depends on 1)

The method of claim 1, wherein the amount is about 135 mg per day.

### Claim 19 (depends on 1)

The method of claim 1, wherein the amount is about 100 mg per day.

### Claim 20

A method of treating a proliferative disease in a mammal, which comprises administering to the mammal having or suspected to have the proliferative disease, a therapeutically effective amount of the compound of Formula I:
or a pharmaceutically acceptable salt or solvate thereof, wherein the therapeutically effective amount is about 150 mg per day.

### Claim 21 (depends on 1)

The method of claim 1, wherein the compound is administered intermittently.

### Claim 22 (depends on 1)

The method of claim 1, wherein the compound is administered continuously.

### Claim 23 (depends on 1)

The method of claim 1, wherein the proliferative disease is cancer.

### Claim 24 (depends on 23)

The method of claim 23, wherein the cancer is leukemia.

### Claim 25 (depends on 24)

The method of claim 24, wherein the leukemia is an acute leukemia.

### Claim 26 (depends on 25)

The method of claim 25, wherein the leukemia is acute myeloid leukemia.

### Claim 27 (depends on 24)

The method of claim 24, wherein the leukemia is promyelocytic leukemia.

### Claim 28 (depends on 24)

The method of claim 24, wherein the leukemia is acute lymphoblastic leukemia.

### Claim 29 (depends on 20)

The method of claim 20, wherein the patient is relapsed or refractory.

### Claim 30 (depends on 23)

The method of claim 23, wherein the patient is relapsed.

### Claim 31 (depends on 23)

The method of claim 23, wherein the patient is refractory.

### Claim 32 (depends on 1)

The method of claim 1, wherein the patient is relapsed or refractory to a FLT3 kinase inhibitor.

### Claim 33 (depends on 6)

The method of claim 6, wherein the acute myeloid leukemia is relapsed or refractory to PKC-412, MLN-518, CEP-701, CT 53518, CT-53608, CT-52923, D-64406, D-65476, AGL-2033, AG1295, AG1296, KN-1022, KW-2449, SU5416, SU5614, SU11248, L-00021649, BAY-43-9006, imatinib, CHIR-258, cytarabine, azacytidine, daunorubicin, idarubicin, doxorubicin, decitabine, fludarabine, clofarabine, troxacitabine, mitoxantrone, pixantrone, etoposide, thioguanine, vorinostat, sapacitabine, gemtuzumab ozogamicin, all-trans retinoic acid (ATRA), melphalan, oxaliplatin, cisplatin, carboplatin, satraplatin, busulfan or a combination thereof.

### Claim 34 (depends on 1)

The method of claim 1, further comprising administering a therapeutically effective amount of a second therapeutic agent.

### Claim 35 (depends on 34)

The method of claim 34, wherein the second therapeutic agent is an anticancer agent.

### Claim 36 (depends on 35)

The method of claim 35, wherein the anticancer agent is selected from the group consisting of PKC-412, MLN-518, CEP-701, CT 53518, CT-53608, CT-52923, D-64406, D-65476, AGL-2033, AG1295, AG1296, KN-1022, KW-2449, SU5416, SU5614, SU11248, L-00021649, BAY-43-9006, imatinib, CHIR-258, cytarabine, azacytidine, daunorubicin, idarubicin, doxorubicin, decitabine, fludarabine, clofarabine, troxacitabine, mitoxantrone, pixantrone, etoposide, thioguanine, vorinostat, sapacitabine, gemtuzumab ozogamicin, all-trans retinoic acid (ATRA), melphalan, oxaliplatin, cisplatin, carboplatin, satraplatin or busulfan.

### Claim 37 (depends on 1)

The method of claim 1, further comprising a diagnostic step for determining the presence of a constitutively activating FLT3 mutant.

### Claim 38 (depends on 1)

The method of claim 1, wherein the compound of formula I, or a pharmaceutically acceptable salt, or solvate thereof is administered orally.

### Claim 39 (depends on 1)

The method of claim 1, wherein the compound of formula I, or a pharmaceutically acceptable salt, or solvate thereof is administered parenterally.

### Claim 40 (depends on 1)

The method of claim 1, wherein the compound of formula I, or a pharmaceutically acceptable salt, or solvate thereof is administered intravenously.

### Claim 41 (depends on 1)

The method of claim 1, wherein the compound of formula I, or a pharmaceutically acceptable salt, or solvate thereof, is administered once per day for one week, two weeks, or three weeks.

### Claim 42 (depends on 1)

method of claim 1, wherein the compound of formula I, or a pharmaceutically acceptable salt, or solvate thereof, is administered once per day for fourteen days.

### Claim 43 (depends on 1)

The method of claim 1, wherein the compound of formula I, or a pharmaceutically acceptable salt, or solvate thereof, is administered once per day for twenty eight days.

### Claim 44 (depends on 1)

The method of claim 1, wherein the administration is followed by a rest period, during which the compound of Formula I, or a pharmaceutically acceptable salt, or solvate thereof is not administered.

### Claim 45 (depends on 44)

The method of claim 44, wherein the rest period is one, two, three, four, five, six, or seven days; two, three, or four weeks.

### Claim 46 (depends on 7)

The method of claim 7, wherein the mammal with the refractory leukemia has a constitutively activating FLT3 mutation.

### Claim 47 (depends on 25)

The method of claim 25, wherein the mammal with leukemia has a FLT3 missense mutation.

### Claim 48 (depends on 47)

The method of claim 47, wherein the FLT3 missense mutation is at amino acid D835.

### Claim 49 (depends on 6)

The method of claim 6, wherein the patient with acute myeloid leukemia has a FLT3 internal tandem duplication mutation.

### Claim 50 (depends on 6)

The method of claim 6, wherein the patient with acute myeloid leukemia has a FLT3 point mutation.

### Claim 51 (depends on 6)

The method of claim 6, wherein a treatment with the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof enables the patient to receive an allogeneic hematopoietic stem cell transplant.

### Claim 52 (depends on 51)

The method of claim 51, wherein the method further comprises an allogeneic hematopoietic stem cell transplant.

### Claim 53 (depends on 23)

The method of claim 23, wherein the cancer is a solid tumor.

### Claim 54 (depends on 23)

The method of claim 23, wherein the cancer is a bladder cancer, breast cancer, cervical cancer, CNS cancer, colon cancer, esophageal cancer, head and neck cancer, liver cancer, lung cancer, nasopharyngeal cancer, neuroendocrine cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, salivary gland cancer, small cell lung cancer, skin cancer, stomach cancer, testicular cancer, thyroid cancer, uterine cancer, gastrointestinal stromal tumor, melanoma, mast cell tumor, neuroblastoma, germ cell tumor hematologic malignancy.

### Claim 55

A spray-dried pharmaceutical composition comprising a compound of Formula I,
or a pharmaceutically acceptable salt or solvate thereof, and hydroxypropyl-β-cyclodextrin.

### Claim 56 (depends on 55)

The pharmaceutical composition of claim 55, wherein the compound is a dihydrochloride salt.

### Claim 57 (depends on 55)

The pharmaceutical composition of claim 55, wherein the solvate is a methanol solvate.

### Claim 58 (depends on 55)

The pharmaceutical composition of claim 55 comprising the compound of Formula I and hydroxypropyl-β-cyclodextrin in a ratio of about 1:10 based on weight.

### Claim 59 (depends on 55)

The pharmaceutical composition of claim 55, wherein the composition is formulated for single dose administration.

### Claim 60 (depends on 55)

The pharmaceutical composition of claim 55, wherein the composition is formulated for oral administration.
